RTP Mobile Logo
Ovarian Cancer Update, Issue 3, 2011
Released January 2012

Featuring interviews with Drs Amit M Oza, David R Spriggs, Don S Dizon and Gini Fleming. (Audio Content)

CE Disclosures and Faculty Information


    Management of ovarian cancer (OC) includes optimal surgical debulking followed by postoperative chemotherapy and, in most cases, subsequent medical management when the disease recurs. Although many single-agent and combination chemotherapy regimens have been studied, only recently have antibody and small-molecule growth-inhibitory targeted agents been integrated into the OC research milieu. It is hoped that the results from these trials will lead to the emergence of new therapeutic agents and changes or enhancements in the indications for existing treatment strategies, ultimately improving the duration and quality of life for patients with metastatic OC. To bridge the gap between research and patient care, this issue of Ovarian Cancer Update features one-on-one discussions with leading gynecologic oncology investigators. By providing information on the latest research developments, this activity attempts to assist medical and gynecologic oncologists with the formulation of therapeutic strategies, which in turn facilitates optimal patient care.


    • Use case-based learning to develop individualized strategies for the care of patients with suboptimally and optimally debulked Stage II to Stage III OC, including the use of intraperitoneal versus intravenous chemotherapy.
    • Consider emerging data focused on the use of angiogenesis inhibition when designing front-line and maintenance therapeutic strategies for patients with OC.
    • Formulate an evidence-based algorithm for the systemic treatment of recurrent platinum-sensitive and platinum-resistant OC.
    • Offer BRCA testing to appropriately selected patients with OC to better facilitate discussions about prognosis, optimal treatment selection and the option of clinical trial participation with promising novel agents.
    • Develop an understanding of the unique mechanisms of action and emerging efficacy and toxicity profiles of investigational agents in OC to effectively prioritize clinical trial opportunities for appropriate patients.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Fleming had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr OzaConsulting Agreement: AstraZeneca Pharmaceuticals LP; Honoraria: Sanofi. Dr SpriggsAdvisory Committee: AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Lilly USA LLC, ZIOPHARM Oncology Inc. Dr DizonConsulting Agreements: Amgen Inc, Centocor Ortho Biotech Services LLC, Genentech BioOncology, Johnson & Johnson Pharmaceuticals.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc and Genentech BioOncology.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2012
    Expiration date: January 2013

Acknowledge and close

Listen to audio:
Ovarian Cancer Update, Issue 3, 2011
Released January 2012

Featuring interviews with Drs Amit M Oza, David R Spriggs, Don S Dizon and Gini Fleming. (Audio Content)

Read print: